These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 7961868)
21. The high affinity calcium-binding site involved in protein C activation is outside the first epidermal growth factor homology domain. Rezaie AR; Esmon NL; Esmon CT J Biol Chem; 1992 Jun; 267(17):11701-4. PubMed ID: 1601845 [TBL] [Abstract][Full Text] [Related]
22. Characterization of gamma-carboxyglutamic acid residue 21 of human factor IX. Wolberg AS; Li L; Cheung WF; Hamaguchi N; Pedersen LG; Stafford DW Biochemistry; 1996 Aug; 35(32):10321-7. PubMed ID: 8756687 [TBL] [Abstract][Full Text] [Related]
23. The importance of specific gamma-carboxyglutamic acid residues in prothrombin. Evaluation by site-specific mutagenesis. Ratcliffe JV; Furie B; Furie BC J Biol Chem; 1993 Nov; 268(32):24339-45. PubMed ID: 8226983 [TBL] [Abstract][Full Text] [Related]
24. A chimeric protein C containing the prothrombin Gla domain exhibits increased anticoagulant activity and altered phospholipid specificity. Smirnov MD; Safa O; Regan L; Mather T; Stearns-Kurosawa DJ; Kurosawa S; Rezaie AR; Esmon NL; Esmon CT J Biol Chem; 1998 Apr; 273(15):9031-40. PubMed ID: 9535891 [TBL] [Abstract][Full Text] [Related]
25. Site-directed mutagenesis but not gamma-carboxylation of Glu-35 in factor VIIa affects the association with tissue factor. Persson E; Nielsen LS FEBS Lett; 1996 May; 385(3):241-3. PubMed ID: 8647260 [TBL] [Abstract][Full Text] [Related]
26. Genetic analysis of a large kindred exhibiting type I protein C deficiency and associated thrombosis. Tomczak JA; Ando RA; Sobel HG; Bovill EG; Long GL Thromb Res; 1994 May; 74(3):243-54. PubMed ID: 7913773 [TBL] [Abstract][Full Text] [Related]
27. An abnormal protein C (protein C Yonago) with an amino acid substitution of Gly for Arg-15 caused by a single base mutation of C to G in codon 57 (CGG-->GGG). Deteriorated calcium-dependent conformation of the gamma-carboxyglutamic acid domain relevant to a thrombotic tendency. Mimuro J; Muramatsu S; Kaneko M; Yoshitake S; Iijima K; Nakamura K; Sakata Y; Matsuda M Int J Hematol; 1993 Jan; 57(1):9-14. PubMed ID: 8477066 [TBL] [Abstract][Full Text] [Related]
28. The role of Phe-92 in the Ca(2+)-induced conformational transition in the C-terminal domain of calmodulin. Meyer DF; Mabuchi Y; Grabarek Z J Biol Chem; 1996 May; 271(19):11284-90. PubMed ID: 8626680 [TBL] [Abstract][Full Text] [Related]
29. Role of the hexapeptide disulfide loop present in the gamma-carboxyglutamic acid domain of human protein C in its activation properties and in the in vitro anticoagulant activity of activated protein C. Zhang L; Castellino FJ Biochemistry; 1991 Jul; 30(27):6696-704. PubMed ID: 1905953 [TBL] [Abstract][Full Text] [Related]
30. Gla domain-mutated human protein C exhibiting enhanced anticoagulant activity and increased phospholipid binding. Sun YH; Shen L; Dahlbäck B Blood; 2003 Mar; 101(6):2277-84. PubMed ID: 12446455 [TBL] [Abstract][Full Text] [Related]
31. Protein S Gla-domain mutations causing impaired Ca(2+)-induced phospholipid binding and severe functional protein S deficiency. Rezende SM; Lane DA; Mille-Baker B; Samama MM; Conard J; Simmonds RE Blood; 2002 Oct; 100(8):2812-9. PubMed ID: 12351389 [TBL] [Abstract][Full Text] [Related]
33. Construction, expression, and characterization of a chimera of factor IX and factor X. The role of the second epidermal growth factor domain and serine protease domain in factor Va binding. Hertzberg MS; Ben-Tal O; Furie B; Furie BC J Biol Chem; 1992 Jul; 267(21):14759-66. PubMed ID: 1634519 [TBL] [Abstract][Full Text] [Related]
34. Val(659)-->Glu mutation within the transmembrane domain of ErbB-2: effects measured by (2)H NMR in fluid phospholipid bilayers. Sharpe S; Barber KR; Grant CW Biochemistry; 2000 May; 39(21):6572-80. PubMed ID: 10828974 [TBL] [Abstract][Full Text] [Related]
35. Construction, expression, and properties of a recombinant chimeric human protein C with replacement of its growth factor-like domains by those of human coagulation factor IX. Yu S; Zhang L; Jhingan A; Christiansen WT; Castellino FJ Biochemistry; 1994 Jan; 33(3):823-31. PubMed ID: 8292611 [TBL] [Abstract][Full Text] [Related]
36. Interference of blood-coagulation vitamin K-dependent proteins in the activation of human protein C. Involvement of the 4-carboxyglutamic acid domain in two distinct interactions with the thrombin-thrombomodulin complex and with phospholipids. Freyssinet JM; Beretz A; Klein-Soyer C; Gauchy J; Schuhler S; Cazenave JP Biochem J; 1988 Dec; 256(2):501-7. PubMed ID: 2851994 [TBL] [Abstract][Full Text] [Related]
37. The effect of Arg306-->Ala and Arg506-->Gln substitutions in the inactivation of recombinant human factor Va by activated protein C and protein S. Egan JO; Kalafatis M; Mann KG Protein Sci; 1997 Sep; 6(9):2016-27. PubMed ID: 9300501 [TBL] [Abstract][Full Text] [Related]
38. Two mutations in the promoter region of the human protein C gene both cause type I protein C deficiency by disruption of two HNF-3 binding sites. Spek CA; Greengard JS; Griffin JH; Bertina RM; Reitsma PH J Biol Chem; 1995 Oct; 270(41):24216-21. PubMed ID: 7592627 [TBL] [Abstract][Full Text] [Related]
40. Calcium-binding sites of the thrombin-thrombomodulin-protein C complex: possible implications for the effect of platelet factor 4 on the activation of vitamin K-dependent coagulation factors. Yang L; Rezaie AR Thromb Haemost; 2007 Jun; 97(6):899-906. PubMed ID: 17549291 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]